Contemporary Outcomes of Vertebral Artery Injury: A Ten-Year Single-Center Experience  by Alterman, Daniel M. et al.
t
p
w
v
(
q
P
R
(
p
t
m
i
C
s
2
a
i
m
c
JOURNAL OF VASCULAR SURGERY
December 20111852 Abstractsa suspected paradoxical embolus to the intestines (overall mortality 11%).
The eight surviving patients were discharged to home within 48 hours of the
intervention and had normal PA pressures without any evidence of right
heart strain on echocardiogram performed one month after their CDTT
procedure.
Conclusions: Massive or submassive PE can be treated safely with
CDTT in a community hospital setting. This can reduce the need for lengthy
ICU stays, shorten overall hospital length of stay, eliminate the need for
home oxygen therapy, and restore right heart function with an acceptable
mortality rate. Development of institutional CDTT expertise in conjunction
with protocols to administer this therapy early in the course of massive and
submassive PE may yield significant mortality and morbidity benefits in
community hospitals.
Treatment of Congenital Vascular Malformations Using a Multidisci-
plinary Approach: Results of a Prospective Study
Michael E. Lidsky, JovanN.Markovic, Cynthia K. Shortell, DukeUniversity
Medical Center, Durham, NC
Background: Vascular malformations (VM) are a rare and complex
group of lesions which may present serious pitfalls in diagnosis and manage-
ment. We sought to evaluate the safety and efficacy of our previously
described imaging protocol and therapeutic algorithm in the treatment of
low flow and high flow vascular malformations in a large series of patients.
Methods: A prospective database of all patients treated by the multidisci-
plinary vascular malformation team at our institution between 2006 and 2011
was reviewed. Management decisions were based on patients’ clinical profile as
well as critical lesion characteristics, and included conservative care, sclerother-
apy, embolization, surgical resection, or a combination of these modalities
(Fig). Treatment goals were established by the patient and physician at the time
of initial evaluation. An outcomes grading system based on patient and physi-
cian derived treatment goals, and assessment of response to management was
applied (1worse; 2unchanged, 3significantly improved, 4completely
resolved), and post-procedural complications were identified.
Results: The 136 vascular malformations in 135 patients included 59
(43.7%) males and 76 (56.3%) females, ranging in age from under 1 year to 68
years (mean 25.3 17.0). In order to facilitate application of the therapeutic
algorithm, all patients underwent dceMRI to determine critical lesion charac-, 2 pts
Methods: We performed a retrospective, single-center review from a
level I trauma center for the previous 10 years of all VAI. Injuries were
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iively, 38 (36.2%) were treated with sclerotherapy (sodium tetradecyl sulfate,
olidocanol, and/or ethanol), 18 (17.1%)were surgically resected, and8 (7.6%)
ere managed with a combination of modalities. Of the 31 (22.8%) high flow
ascular malformations (HFVM), 8 (25.8%) were managed conservatively, 8
25.8%) were treated with transcatheter arterial embolization, 6 (19.4%) re-
uired embolization followed by sclerotherapy, and 5 (16.1%) were resected.
atients in all groups managed conservatively had minimal alteration in status.
esponse to sclerotherapy in the LFVM group resulted in improvement in 32
84.2%) patients, surgical resection resulted in improvement in 16 (88.9%)
atients, and combination therapy resulted in improvement in 8 (100%) pa-
ients. Treatment with embolization in the HFVM group resulted in improve-
ent in 7 (87.5%) patients, while combination therapy resulted in improvement
n 6 (100.0%), and surgical resection led to improvement in 4 (80%) [Table].
omplications were observed in 6 (6.8%) patients treated for LFVMs (0 with
odium tetradecyl sulfate or polidocanol, 4 with ethanol, 2 with resection), and
(7.4%) patients treated for HFVMs with embolization or combination ther-
py.
Conclusion: In this large cohort of vascular malformation patients,
mplementation of the proposed diagnostic and therapeutic algorithms in a
ultidisciplinary setting resulted in favorable outcomes with an acceptable
omplication rate in this challenging patient population.
Fig.
teristics including flow quality and lesion extension. Of the 105 (77.2%) low
flow vascular malformations (LFVM), 23 (21.9%) were managed conserva-
Table.
Type N (%) Treatment
Treated N
(%)
Outcomes N (%)
Complications
N (%)
Specific
complicationsWorse No change
Significantly
improved
Completely
resolved
LFVM 105
(77.2%)
Conservative
management
23 (21.9%) 2 (8.7%) 18 (78.2%) 2 (8.7%) 1 (4.3%) 0 (0%)
Foam
sclerotherapy
31 (29.5%) 0 (0%) 2 (6.5%) 21 (67.7%) 8 (25.8%) 0 (0%)
Ethanol
sclerotherapy
7 (6.7%) 0 (0%) 4 (57.1%) 3 (42.9%) 0 (0%) 4 (57.1%) DVT, ulceration,
bradycardia/
oxygen
desaturation
Resection 18 (17.1%) 0 (0%) 2 (11.1%) 3 (16.7%) 13 (72.2%) 2 (11.1%) PE, Infection
Combination
therapy
8 (7.6%) 0 (0%) 0 (0%) 7 (87.5%) 1 (12.5%) 0 (0%)
HFVM
31 (22.8%)
Conservative
management
8 (25.8%) 0 (0%) 6 (75.0%) 1 (12.5%) 1 (12.5%) 0 (0%)
Embolization 8 (25.8%) 1 (12.5%) 0 (0%) 6 (75.0%) 1 (12.5%) 1 (12.5%) Hemorrhage
Embolization 
sclerotherapy
6 (19.4%) 0 (0%) 0 (0%) 5 (83.3%) 1 (16.7%) 1 (16.7%) Ulceration
Resection 5 (16.1%) 0 (0%) 1 (20%) 1 (20%) 3 (60%) 0 (0%)Tabular data do not include 18 pts lost to follow up (4 HFVM, 14 LFVM)
Contemporary Outcomes of Vertebral Artery Injury: A Ten-Year Sin-
gle-Center Experience
Daniel M. Alterman, Todd A. Nickloes, Stanley J. Kurek, Oscar H. Grandas,
Scott L. Stevens, Mitchell H. Goldman, Michael B. Freeman, University of
Tennessee Graduate School of Medicine, Knoxville, Tenn
Background: Vertebral artery injury (VAI) associated with cervical
trauma is being increasingly recognized with more aggressive screening.
Disparate results from previous literature have led to uncertainty of the
significance, natural history and optimal therapy for VAI.treated with laser, and 1 pt who died prior to initiation of treatment.
dentified from search of administrative trauma database, a resident-run
orking database, and all radiology dictations for the same period. VAI were
lassified according to segmental involvement, Denver grading scale, and
aterality. Analysis of associated injuries, demographics, neurologic out-
ome, mortality, length of stay, treatment plan, and follow-up imaging was
lso performed.
Results: Fifty-one patients with VAI were identified from 2001-2011
rom a total 36,942 trauma admissions (0.13% incidence). Associated inju-
ies were significant with an average NISS 29.6. Penetrating trauma oc-
urred in 14%. Cervical spine fracture was present in 88% with VAI. Diag-
osis was obtained with CT angiography in 95%. Screening was prompted by
njury pattern or high-risk mechanism in all cases. Injuries classified accord-
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Volume 54, Number 6 Abstracts 1853ing to the Denver grading scale were; grades 124%, 235%, 34%,
435%, and 52%. Distribution across segments included; V118%,
V267%, V331%, and V46%. Only one posterior circulation stroke was
attributable to VAI. Overall mortality was 8% being associated with other
injuries. Treatment rendered was antiplatelet therapy (50%), observation
(29%), warfarin (17%) or stent (4%). Follow-up was obtained with 13% (n
6) of survivors. CT angiogram or MRA demonstrated injury stability in 4
patients and resolution in 2 patients. Accuracy of the administrative trauma
database was 53% compared with 96% for the resident-runworking database.
Conclusions:Neurologic sequelae attributable to VAI was rare. Grade
of VAI or vertebral artery segment did not correlate with morbidity. Poste-
rior circulation stroke was low. Patient morbidity and mortality was attrib-
utable to severe associated injuries. Of those seen at follow-up, injury
resolution or stability was documented by CT angiogram. A conservative
approach with either observation or anti-thrombotic therapy is suggested.
Our search strategy urges awareness of the limitations of administrative
databases for retrospective vascular study.
Carotid Endarterectomy is More Cost-Effective Than Carotid Artery
Stenting
W C Sternbergh, III, Gregory D. Crenshaw, Taylor A. Smith,
Hernan A. Bazan, Ochsner Clinic Foundation, New Orleans, La
Background: In a clinical environment where there may be emerging
clinical equipoise between two therapies, the cost of delivering that intervention
becomes increasingly important. Carotid Endarterectomy (CEA) and carotid
artery stenting (CAS) have both demonstrated a reduction in long-term stroke
risk after successful intervention. While the CREST trial demonstrated no
significant differences between CAS and CEA regarding the peri-operative risk
when the primary endpoint of CVA, death orMIwas examined, ameta-analysis
of European randomized prospective trials in symptomatic patients strongly
favored CEA as the safer procedure. In the United States, the percentage of
gross domestic product (GDP) devoted to medical care continues to rise at a
rate that is unsustainable. Going forward, more efficient use of health care
dollars will be essential. Preferential use of the most cost-effective therapy for a
given clinical problem should be part of the solution. In an effort to further
compare treatment of carotid disease, we analyzed hospital cost and clinical
outcome data of patients undergoing CEA and CAS.
Methods: A retrospective analysis of hospital cost and 30-day out-
comes was performed on patients undergoing CEA and CAS between
1/1/2008 and 9/30/2010 at a single tertiary referral institution. The
hospital patient database was queried using CPT codes to search for those
patients who had either undergone CEA (CPT 35301) or CAS with embolic
protection (CPT 37215) during the specified period.
Clinical Definitions: Patients were considered to be symptomatic
from their carotid disease if they had experienced ipsilateral amarousis fugax,
transient ischemic attack (TIA) or stroke. Urgent interventions were defined
as those patients admitted with an acute cerebral or ocular ischemic episode
who were found to have significant ipsilateral carotid disease and underwent
intervention during the index hospitalization. The 30-day clinical major
adverse event was defined as a composite of any stroke, death and MI.
Cost Calculation: The institution’s financial department performed an
analysis of hospital cost (not charges) on the main patient cohorts and sub-
groups detailed above. Professional fees were not included in this analysis. The
cost of the procedure was based on a cost accounting method using the relative
value unit (RVU) system.Eachprocedure or itemcharged to a casewas assigned
an RVU. Costs were then calculated based on the relative RVU valuation. The
cost items were assigned to the following cost centers: labor expense, supply
expense, facility/equipment expense, and miscellaneous. Once the total ex-
pense for the index hospitalization was calculated, it was normalized to 2010
costs based on the medical consumer price index. Statistical analysis was per-
formed with Wilcox’s analysis, X2, and Fisher’s exact test.
Results: Three hundred and fifteen patients underwent either CEA
(n  174) or CAS (n  141) between 1/1/2008 and 9/30/2010. Nine
patients were excluded from the primary cohort (all receiving CAS) because
they had other associated procedures during the index hospitalization which
would have biased the economic analysis. Thus, the final examined cohort
was 306 patients who underwent CEA (n  174) or CAS (n  132).
Demographics: There was a strong trend towards more symptomatic
patients in the CEA cohort (44%, n 78) compared to the CAS group (34%
n  45) which did not attain statistical significance (P  .058). The
frequency of urgent intervention was similar between groups [CEA 12.6%
(n  22) vs CAS 10.0% (n  14); P  .72). The mean age in the CEA and
CAS groups was 70.1 9.8 yrs. and 72.0 9.7 yrs, respectively (P .36).
There was a trend towards a higher prevalence of medical co-morbidities in
the CAS cohort compared to the CEA cohort (94.5% vs 88.9%, respectively;
P  .07), with a higher prevalence of CAD (61% vs 37%, P  ,0001) and
CHF (18.2 vs 5.2%, P  .0003) in the CAS cohort.
Hospital Cost: The hospital cost for CAS ($9426  5776) was 40%
greater than that ofCEA ($67343935,P .0001). This cost differential was
driven by a mean difference of $3667 in higher direct supply costs in the CAS
group ($5634  3384) compared to the CEA group ($1967  1967, P 
.0001). There were no significant differences betweenCEA andCAS in regards
to labor or facility costs (Fig 1). Subgroup analysis was performed comparing
the cost of CEA and CAS for asymptomatic, symptomatic, elective, and urgentrocedures (Fig 2). In all sub-group cohort comparisons, there was a consistent
ncrease in cost for CAS compared to CEA. All of these differences were
tatistically significant (P .001) except the urgent subgroup (P .07).Cost of
AS and CEA was also examined in relation to patient enrollment in a trial or
egistry. Patients undergoing CAS who were enrolled in a trial or registry
53.8%, n  71) incurred significantly less cost ($7779  3525) compared to
hose who were not (n  61, $11,279  7114, P  .0004). There were no
ignificant differences in cost for patients undergoingCEA regarding trial status.
Clinical Outcome: The 30-day major adverse event rate (stroke,
eath, MI) was 2.3% in the CEA group and 3.8% in the CAS group (P .5).
Length of Stay: Overall LOS was 2.1 days in both CEA and CAS
roups (P .9). LOS in patients with symptomatic disease (2.9-3.6 days) or
ho had urgent intervention (7.3-7.5 days) was much greater than patients
ndergoing intervention electively or for asymptomatic disease (1.3-1.4
ays). The LOS between CEA and CAS was similar in all these subgroups.
Conclusions: The hospital cost of CAS was demonstrated to be 40%
reater than CEA. The cost differential in the present study was driven
argely by the significant differential in direct supply costs in the CAS group
f $3667. Current hospital costs for a carotid stent and embolic protection
evice is approximately $3750 - 4100 compared to $90-100 for a synthetic
arotid patch used with endarterectomy. Clearly, the cost differential of
hese two therapies was due to the relatively high cost of the interventional
roducts required for CAS. There was no net significant offsetting savings in
acility or labors costs for the CAS patients as the length of stay was similar
etween the two treatment groups. This is the first carotid economic study
o examine multiple treatment subgroups. Patients with urgent intervention
ncurred costs much greater in both groups than those who where treated
lectively. This cost differential was driven by the much greater LOS for
rgent cases (7.3-7.5 days) compared with elective cases (1.3-1.4 days).
dditional cost for diagnostic imaging in these cases also likely contributed.
atients being treated for symptomatic disease likewise had greater costs
han those treated for asymptomatic disease. Increased LOS in the symp-
omatic groups (2.9-3.6 days) verses the asymptomatic group (1.3-1.4 days)
ertainly played a role. The relative cost trends between CAS and CEA seen
n the primary cohorts were not altered in any subgroup. CAS was consis-
ently more costly in each subgroup. A novel finding of this study was that
AS patients enrolled in a trial or registry had costs that were significantly
ess than those who were treated with CAS outside of a trial. These data refute
he notion that the differential in cost between CEA and CAS is due, in part, to
dditional costs associated with protocol-mandated imaging and testing for
atients enrolled in a trial or registry. The present study represents a “realworld”
ost analysis of CEA and CAS performed at a single, tertiary referral center with
ignificant expertise and experience in both therapies. As such, it may provide a
ore realistic view of costs compared to data generated from clinical trials.
hile a small number of patients were part of randomized prospective trials
CREST, ACT-1), most treatment decisions were made by the intervening
hysician. Selection bias is a clear concern and could confound attempts to
ompare the treatment groups. In an attempt to decrease this possibility, we
xcluded patients who had other major procedures during the index hospital-
zation, or who were not admitted primarily because of TIA, stroke or carotid
isease. Did the treatment groups have disparate demographics or clinical
resentation? Patients undergoing CEA were more likely to have symptomatic
isease when compared to those undergoing CAS. As symptomatic status is a
ery strong risk factor for peri-procedural stroke, this difference would suggest
hat theCEAgroupwas at higher risk of a poor outcome, potentially biasing the
esults against CEA. Conversely, in the CAS group there was a higher preva-
ence of CAD and CHF, suggesting that group had a higher potential cardiac
orbidity, potentially biasing the results against CAS. Patient age and other
edical co-morbidities were similar between treatment groups. In conclusion,
AS was associated with a 40% cost premiumwhen compared to CEA, and did
ot provide any improvement in clinical outcome or LOS. All subgroups had
imilar cost trends. Given the lack of clinical improvement and its cost premium,
AS cannot be considered routinely cost-effective for the treatment of carotid
rtery disease.Fig 1.
